COMMUNIQUÉS West-GlobeNewswire

-
KemPharm Announces Enhancements to U.S. and Global Intellectual Property Estate
29/01/2019 -
National Healthcare Economics and Policy Expert Ruben Jose King-Shaw Jr Joins CURE Pharmaceutical’s Board of Directors
29/01/2019 -
IMV Announces Clinical Update for DPX-Survivac Program in Ovarian Cancer Following Positive Feedback from U.S. FDA
29/01/2019 -
Neurocrine Biosciences and Voyager Therapeutics Form Strategic Development and Commercialization Collaboration for Parkinson’s Disease and Friedreich’s Ataxia
29/01/2019 -
Aravive to Host Key Opinion Leader Breakfast Symposium on AVB-S6-500 and the GAS6-AXL Pathway on February 5, 2019
29/01/2019 -
FACIT and Triphase Accelerator Announce New Partnership with Celgene for First-in-class WDR5 Leukemia Therapy
29/01/2019 -
LHC Group Appoints National Healthcare Veteran Teri G. Fontenot to Board of Directors
29/01/2019 -
Emerald Health Therapeutics’ Licensed Endo Product Line Gains Boost with Entry into Whole Foods Market Stores Across US
29/01/2019 -
Managers’ transactions
29/01/2019 -
Nicox : Aval de la FDA américaine pour l'Investigational New Drug du NCX 4251 pour une étude de phase 2 dans la blépharite
29/01/2019 -
Nicox Announces U.S. FDA Acceptance of Investigational New Drug Application for NCX 4251 Phase 2 Trial in Blepharitis
29/01/2019 -
Biocartis Group NV: DISCLOSURE OF OUTSTANDING VOTING SECURITIES
29/01/2019 -
INNATE PHARMA RECEIVES FDA FAST TRACK DESIGNATION FOR IPH4102 IN RELAPSED OR REFRACTORY SÉZARY SYNDROME
29/01/2019 -
INNATE PHARMA REÇOIT LE STATUT « FAST TRACK » DE LA FOOD AND DRUG ADMINISTRATION (FDA) POUR IPH4102 CHEZ LES PATIENTS PRÉSENTANT UN SYNDROME DE SÉZARY EN RECHUTE OU RÉFRACTAIRE
29/01/2019 -
Cancer Genetics, Inc. Announces Pricing of $3.5 Million Public Offering of Common Stock
29/01/2019 -
Kiniksa Pharmaceuticals, Ltd. Announces Proposed Public Offering and Concurrent Private Placement
28/01/2019 -
IMV to Present at 2019 BIO CEO & Investor Conference
28/01/2019 -
Akorn Announces New Executive and Board Appointments
28/01/2019 -
Myriad to Announce Fiscal Second-Quarter 2019 Financial Results on February 5, 2019
28/01/2019
Pages